KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Invested Capital (2016 - 2026)

AbbVie has reported Invested Capital over the past 14 years, most recently at $61.8 billion for Q4 2025.

  • Quarterly Invested Capital fell 12.35% to $61.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.8 billion through Dec 2025, down 12.35% year-over-year, with the annual reading at $61.8 billion for FY2025, 12.35% down from the prior year.
  • Invested Capital was $61.8 billion for Q4 2025 at AbbVie, up from -$660.0 million in the prior quarter.
  • Over five years, Invested Capital peaked at $92.1 billion in Q4 2021 and troughed at -$660.0 million in Q3 2025.
  • The 5-year median for Invested Capital is $17.7 billion (2023), against an average of $29.3 billion.
  • Year-over-year, Invested Capital soared 438.39% in 2021 and then crashed 108.18% in 2025.
  • A 5-year view of Invested Capital shows it stood at $92.1 billion in 2021, then decreased by 12.54% to $80.6 billion in 2022, then dropped by 13.38% to $69.8 billion in 2023, then rose by 0.98% to $70.5 billion in 2024, then dropped by 12.35% to $61.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Invested Capital are $61.8 billion (Q4 2025), -$660.0 million (Q3 2025), and $1.9 billion (Q2 2025).